ArticleFrontiers in immunology2021
Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 42 citations in OpenAlex.
- CD8+ T cell activation occurs 24 hours after AAV administration and is driven by muscle promoter specificity.JCI insight · 2026Article
- Challenging the more-is-better dogma: A precision-optimized AAV gene therapy for SMA.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives.MedComm · 2026Review
- Tumor-Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: Underlying mechanisms and mitigating strategies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy.Current medical science · 2026Review
- Immunogenicity of Gene and Cell Therapies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- FromImmune network · 2026Review
- Mechanisms of and mitigating strategies for cellular immune responses to CRISPR-associated nucleases in genome editing therapy.Frontiers in medicine · 2026Review
- Viral vector-based gene therapies in the clinic: An update.Bioengineering & translational medicine · 2026Review
- The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig.AIDS research and human retroviruses · 2025Article
- Dystrophin Restorative and Compensatory Gene Addition Therapies for Duchenne Muscular Dystrophy: Could CRISPRa Provide a Realistic Alternative?Muscles (Basel, Switzerland) · 2025Review
- Key Challenges and Optimization Practices for Non-clinical Evaluation of AAV based Gene Therapy for Central Nervous System Disease.Pharmaceutical research · 2025Review
- Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level.Nature biomedical engineering · 2025Review
- Teaching an old vector new tricks: the surprising versatility of AAV vaccines.Journal of virology · 2025Review
- Identification of a robust promoter in mouse and human hepatocytes by in vivo biopanning of a barcoded AAV library.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Advancing adeno-associated virus for Duchenne muscular dystrophy treatment: Moving beyond rodent models.Molecular therapy. Methods & clinical development · 2025Article
- The curious case of AAV immunology.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Advances in Gene Therapy for Rare Diseases: Targeting Functional Haploinsufficiency Through AAV and mRNA Approaches.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Manish MuhuriHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Wei ZhanHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Yukiko MaedaHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Jia LiHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Anoushka LotunHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Jennifer ChenHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Katelyn SylviaHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Ishani DasguptaHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Motahareh ArjomandnejadHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Thomas NixonHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Allison M KeelerHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Sangeetha ManokaranHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Ran HeHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Qin SuHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Phillip W L TaiHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
Guangping GaoHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, United States.
University of Massachusetts Chan Medical School · US
Funding
Project 4: A permanent off-switch for AAVU19AI149646 · NIAID · UNIVERSITY OF FLORIDA · PI FARZAN, MICHAEL R. · 2020 to 2024
$14.0MViral escape from AAV expressed transgenesP01AI100263 · NIAID · SCRIPPS FLORIDA · PI GAO, GUANGPING · 2012 to 2016
$11.9MViral Vector CoreP01HL131471 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI XUE, WEN · 2016 to 2020
$11.3MSustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9MOligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and LeukodystrophiesR01NS076991 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Guangping Gao · 2012 to 2026
$5.7MNext Generation of Recombinant AAV Serotype Vectors for Gene TherapyR01HL097088 · NHLBI · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING, HERZOG, ROLAND W. · 2010 to 2018
$5.4MDevelop combinatorial non-viral and viral CRISPR delivery for lung diseasesUG3HL147367 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANDERSON, DANIEL G, GAO, GUANGPING · 2018 to 2020
$2.7MNHLBI NIH HHS P01 HL131471NHLBI NIH HHS R01 HL097088NHLBI NIH HHS UG3 HL147367NIAID NIH HHS P01 AI100263NIAID NIH HHS R01 AI121135NIAID NIH HHS U19 AI149646NINDS NIH HHS R01 NS076991
Abstract
Recombinant adeno-associated virus (rAAV) platforms hold promise for
Indexed as
DependovirusGenetic VectorsMicroRNAsAnimalsAntigen PresentationAntigen-Presenting CellsBinding SitesFemaleGenetic TherapyMaleMiceMice, Inbred C57BLTransduction, GeneticTransgenesMicroRNAsadeno-associated virus vectorsantigen presenting cellsgene therapymicroRNAmiR-142miR-223-3pmiR-652-5pmiR-BS
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.